H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a ...

Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with its ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer. Syros late ...

JMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

Philadelphia, Pennsylvania-- (Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or ...

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The company’s shares closed yesterday at $2.73. Nadeau covers the ...

Syros Pharmaceuticals Inc.’s phase III failure with oral retinoic acid receptor alpha agonist tamibarotene in myelodysplastic syndrome (MDS) meant not only severe stock damage but also defaulting on ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the ...

The interiors similarly would be different and would be similar to the EV9 with a clean minimalistic look while it would be ...